Anti‐VEGF pathway inhibitors are an attractive therapy for various cancers but have limited therapeutic effects for glioblastoma, such as improvement of radiation necrosis and improvement of ADL because of reduced edema [26, 27, 28]. The gene discussed is VEGFA; the disease is cancer.